A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy - Test2 - elhamkhani - TriplyDB

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

http://www.wikidata.org/entity/Q28087576

about

Immunometabolism of regulatory T cells Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination Advances in Cancer Immunotherapy in Solid Tumors Immune checkpoint blockade for hematologic malignancies: a review Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious Diseases Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy Medicinal chemistry of adenosine, P2Y and P2X receptors.A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.CD73: A potential biomarker for anti-PD-1 therapy Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3).Targeting CD73 in the tumor microenvironment with MEDI9447.Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.Safety issues of compounds acting on adenosinergic signalling.The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles.Metabolites: deciphering the molecular language between DCs and their environment.Targeting neoantigens to augment antitumour immunity.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Targeting adenosine in cancer immunotherapy: a review of recent progress.Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.The interplay between metabolic remodeling and immune regulation in glioblastoma.Role of extracellular cysteine residues in the adenosine A2A receptor.Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.A covalent antagonist for the human adenosine A2A receptor.2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists.Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling.Next generation of immune checkpoint therapy in cancer: new developments and challenges.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein.Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation

P2860

Q28074509-521F7D76-00FD-4709-92ED-40F3F11128E1 Q28074536-7DDE710A-09A7-468A-A24C-93446A689D81 Q28080113-D793F679-693A-4249-8D65-AFAEAB1EA4B5 Q33645590-776AAA6D-DCCD-4229-AE8B-5C555E70892E Q33849778-22285384-3F57-416F-835B-A76F1BEE991C Q34539323-64CD4A59-3DB3-40B1-9838-60EDEC24136C Q34550649-22696B08-55E2-4493-9A47-643B486D169A Q35873582-DAB0D64B-23D1-4263-B6D7-A068C4334E27 Q36090771-F1A43D7E-9895-471E-81D2-745E57BD42A9 Q36107945-EE5BD843-34B4-4CFC-AD92-E30A45275E85 Q36213059-0934D547-4466-441E-A0D7-C2D3A5EC3C24 Q37224639-CF2B6E41-95B5-4A06-BEBB-8488D33C440F Q37702792-AFEBE05E-C77A-417C-9FA6-FE1A09B725C0 Q38595251-099047EE-CC26-4660-81F9-95BCD70AD519 Q38719858-908C695C-8437-40FA-ACA7-F8566C0A0E90 Q38765118-32D865AE-2874-4476-AA34-6EAC70083791 Q38800033-54BE3A0A-4245-4E00-B7BC-890650396D11 Q38843185-8EBFAA2D-30E5-4111-B762-785AEA9A5C02 Q39003888-ABDEE671-942F-41CA-A47F-A68A0E3FE2BB Q39030292-1F24B13D-D77A-4BC0-9653-16ED544B96F3 Q39149196-D8DD05D9-BA77-4DAD-8D6D-A86374F28CCA Q39161005-AAD7B40D-936F-4062-A8F1-838652A39B1F Q39235260-66702B00-1865-4A11-A50D-1DED08A05FF3 Q39265746-D5306DAA-1C14-498A-B735-DA57181241A7 Q39328710-6B75D446-8EBE-4083-B3E6-5979C283AA6B Q40932261-51F918AD-4A51-4DE9-A458-EE9701E9C1E1 Q41718159-8E8567FD-5F90-4F35-821A-62377459363C Q41763691-D7D553E0-4730-4339-A558-D3B9F07680FA Q46475985-2B654CA2-5807-4E85-9AA7-5979F3CABF71 Q50207906-FF6837C8-A7CC-45F4-89F1-7A9C8E3FE4EE Q52653710-29D9D279-5AE0-49B8-843C-D632284A6F65 Q52689973-927CBA63-44D1-406F-87ED-6FEEA2C1F446 Q55072103-3BF6153F-6BE0-4FFD-A547-A1E68C271FCE Q55106038-DEA623F1-69E6-427C-BACE-416579D20F61 Q58765606-60FFF26B-79C2-4606-83F6-6BE21F5BA5F6

P2860

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

http://www.wikidata.org/entity/Q28087576

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@ast

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@en

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@nl

type

label

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@ast

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@en

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@nl

prefLabel

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@ast

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@en

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@nl

P1433

Q28087576-14ACC49B-A119-4A88-AFEF-53DA353E8CB6

P1476

Q28087576-4BC11500-53AA-48CD-B414-4D2B6687C095

P2093

Q28087576-75840575-EB2C-4DEA-9F3C-DC218E2E508A

Q28087576-AE80950F-4366-4940-9A79-3ECC780F4315

Q28087576-D47C9319-80E8-45DC-A591-F38E1B41BC24

P2860

Q28087576-0023B77A-1FE2-4C7A-8682-8D21A75C49EE

Q28087576-0054C60A-1473-4C93-BBC4-942587F0E8DC

Q28087576-011596F6-2FD6-4E12-864D-A2954B282A87

Q28087576-098927CD-AF1D-4738-94F6-C889EDE3001C

Q28087576-09F2F944-761E-4C30-81DF-4A83BDCE2F26

Q28087576-0AF159E3-9E46-483A-9887-E0D6CAF2CF9D

Q28087576-0FAEE494-73DB-4EDB-B5DE-B3B5A8D76A30

Q28087576-11CAAFDA-36AA-4602-BAE7-C6B0ABD5A71A

Q28087576-124CEE38-11E9-473F-848E-4911C9720530

Q28087576-13AA759F-8BE9-4D03-B5A1-1B8CDBD99CDE

P304

Q28087576-7647D0FC-58CE-4CF3-896A-DB68B4890318

P31

Q28087576-52347B5B-6C55-416C-956B-733B205C5E00

P3181

Q28087576-C2513425-F6A5-41FC-8202-0349A982CCC9

P356

Q28087576-862B4E3C-A89E-40F5-BEA7-82127B26921E

P407

Q28087576-7C4527A9-3BCE-4B9A-8A20-E90B056DDD29

P478

Q28087576-6FB7B900-12F5-4EA1-8CEF-F85D94F82C7B

P577

Q28087576-45B1DEED-0B54-4C2B-9AB4-3455F4544DB2

P5875

Q28087576-B40707FC-1409-43AC-8138-12361F2463B8

P698

Q28087576-D0195EA3-3ABA-4707-A158-2C5221353DA1

P921

Q28087576-D840C8E3-C5B2-4F72-B2FE-C7B06E60D801

P932

Q28087576-2A58836B-1D10-4BBB-AD1E-E98D9F4F58F6

P3181

P356

J.CSBJ.2015.03.008

P1433

Computational and Structural Biotechnology Journal

P1476

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

@en

P2093

Jonathan D. Powell

http://www.w3.org/2001/XMLSchema#string

Robert D. Leone

http://www.w3.org/2001/XMLSchema#string

Ying-Chun Lo

http://www.w3.org/2001/XMLSchema#string

P2860

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The PD-1 pathway in tolerance and autoimmunity

Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth

Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P304

265-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4221062

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CSBJ.2015.03.008

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274737018

http://www.w3.org/2001/XMLSchema#string

P698

25941561

http://www.w3.org/2001/XMLSchema#string

P921

P932

4415113

http://www.w3.org/2001/XMLSchema#string